This is likely going to trade sideways at relatively low volume until we start seein 8-Ks regarding Human Trials and/or the resolution of Governance issues. Buy the dips - it'll pay off in the long run.
Good strategy. Except I would rephrase, "medium-term run"...many, many things happening this fall.
I used to trade in and out 100% back before the FDA approved the HUD/IDE. The reason being that it was considered a major hurdle that could take who knows how long - pretty much same category of risk back then as with biotechs awaiting a binary event during Phase I/II/II Trials - sink, swim, or delay. Then, once the FDA approval of the scaffold was announced, I took a much larger position, and traded around the core -- adding on dips, selling on good news -- for the next couple months, April and May. Once we got closer to the dates of uplisting and trials starting, I just held and didn't sell because of the random chance of news. At this point I could add more, but since August is such a low volume month, I will be twice as patient, and let the stock come to me, not chase. September we are off to the races on enthusiasm over news coming very soon at that point, and when that happens, Frank will run the TV circuit again, I am quite sure, increasing awareness in the financial community, the medical news community, and general public interest as well.